Phase 1–2 Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS

Original Article

T. Miller, M. Cudkowicz, P.J. Shaw, P.M. Andersen, N. Atassi, R.C. Bucelli, A. Genge, J. Glass, S. Ladha, A.L. Ludolph, N.J. Maragakis, C.J. McDermott, A. Pestronk, J. Ravits, F. Salachas, R. Trudell, P.V. Damme, L. Zinman, C.F. Bennett, R. Lane, A. Sandrock, H. Runz, D. Graham, H. Houshyar, A. McCampbell, I. Nestorov, I. Chang, M. McNeill, L. Fanning, S. Fradette, and T.A. Ferguson

N Engl J Med 2020;383:109-119

Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation
Course opens: 
07/08/2020
Course expires: 
07/09/2022

Available Credit

  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation

Course closed

This course closed on Saturday, July 9, 2022 - 11:59pm.